300357.SHE Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
- Market cap
- CNY 11.1B
- P/E
- 25.9x
- P/B
- 3.83x
- ROE
- 17.8%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300357.SHE undervalued?
Graham number300357.SHE trades 109.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd yet.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The c…
Full company profileZhejiang Wolwo Bio-Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 312M | 386M | 501M | 639M | 636M | 808M | 896M | 848M | 925M | 1.06B | 1.21B |
| Gross Profit | 301M | 371M | 472M | 617M | 608M | 773M | 854M | 808M | 881M | 1.01B | 1.16B |
| Operating Income | 151M | 216M | 271M | 343M | 322M | 393M | 396M | 345M | 369M | 414M | 557M |
| EBITDA | 154M | 210M | 260M | 327M | 295M | 366M | 402M | 338M | 361M | 489M | 596M |
| Net Income | 129M | 186M | 233M | 298M | 278M | 338M | 349M | 310M | 318M | 381M | 522M |
| EPS | 0.25 | 0.36 | 0.44 | 0.57 | 0.53 | 0.65 | 0.67 | 0.59 | 0.61 | 0.73 | 1.00 |
| Balance Sheet | |||||||||||
| Total Assets | 697M | 848M | 1.06B | 1.43B | 1.60B | 1.93B | 2.20B | 2.56B | 2.71B | 2.90B | 3.22B |
| Total Liabilities | 41.3M | 47.1M | 62.5M | 76.3M | 76.6M | 135M | 171M | 258M | 250M | 186M | 201M |
| Shareholders' Equity | 656M | 801M | 970M | 1.27B | 1.46B | 1.74B | 1.98B | 2.19B | 2.35B | 2.62B | 2.93B |
| Cash & Short-term Investments | 235M | 186M | 460M | 792M | 891M | 1.02B | 1.14B | 1.29B | 1.31B | 797M | 776M |
| Total Debt | - | - | - | - | 9.81M | 7.81M | 16.3M | 55.6M | 20.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 123M | 159M | 206M | 233M | 256M | 361M | 360M | 388M | 262M | 423M | - |
| Capital Expenditure | 35.9M | 34.7M | 57.8M | 99.8M | 70.2M | 122M | 189M | 209M | 118M | 119M | 44.1M |
| Free Cash Flow | 86.8M | 124M | 149M | 133M | 186M | 238M | 172M | 173M | 144M | 304M | 416M |
| Ratios | |||||||||||
| ROE | 19.7% | 23.2% | 24.0% | 23.5% | 19.1% | 19.5% | 17.6% | 14.2% | 13.5% | 14.5% | 17.8% |
| ROA | 18.5% | 21.9% | 22.0% | 20.9% | 17.4% | 17.5% | 15.9% | 12.1% | 11.7% | 13.1% | 16.2% |
| Net Profit Margin | 41.4% | 48.3% | 46.5% | 46.7% | 43.8% | 41.8% | 38.9% | 36.6% | 34.3% | 35.9% | 43.0% |
| Debt to Equity | - | - | - | - | 0.01x | 0.00x | 0.01x | 0.03x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.04%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 30.3%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 115M | 0.22 | 30.3% |
| 2024 | CNY 97.4M | 0.19 | 30.7% |
| 2023 | CNY 105M | 0.20 | 33.8% |
| 2022 | CNY 105M | 0.20 | 30.2% |
| 2021 | CNY 83.8M | 0.16 | 24.8% |
| 2020 | CNY 94.2M | 0.18 | 33.8% |
| 2019 | CNY 72.7M | 0.14 | 24.4% |
| 2018 | CNY 64.6M | 0.12 | 27.8% |
| 2017 | CNY 40.4M | 0.08 | 21.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.8:1 on May 8, 2019.
Who owns Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
- Insiders 52.06%
- Institutions 6.56%
- Public & others 41.38%
- Shares outstanding 524M
- Free float 263M
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
- Ticker
- 300357.SHE
- ISIN
- CNE100001R58
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,808
- Fiscal year end
- December
- Address
- No. 636, Zhiyuan North Road, Huzhou, China, 313200
- Phone
- 86 57 2883 1088
- Website
- wolwobiotech.com
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The company was founded in 2002 and is headquartered in Huzhou, China.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd management
5- Mr. Guoqi WangFinancial Manager & Head of Accounting Department · born 1974
- Mr. Long JiDeputy Manager of the Marketing Department & Employee Representative Director · born 1988
- Mr. Ziqiang BiDeputy GM & Non-Independent Director · born 1964
- Mr. Zhenwei GuanDeputy GM & Secretary of the Board of Directors · born 1981
- Ms. Mushuang HuDeputy General Manager · born 1991